Revance to Participate in Upcoming Investor Conferences
February 21 2024 - 8:00AM
Business Wire
Revance Therapeutics, Inc. (RVNC) today announced that the
company will be participating in the following investor
conferences.
Cowen 44th Annual Healthcare Conference Chief Executive
Officer, Mark Foley and Chief Financial Officer, Tobin Schilke are
scheduled to participate in a fireside chat on Tuesday, March 5,
2024, at 12:50p.m. EST, in Boston, Massachusetts.
Barclays Global Healthcare Conference 2024 Chief
Executive Officer, Mark Foley, is scheduled to participate in a
fireside chat on Tuesday, March 12, 2024, at 9:30a.m. EST, in
Miami, Florida.
Interested parties can access the live audio webcast for this
conference from the Investor Relations section of the company's
website at www.revance.com. The webcast replay will be available
after the conclusion of the live presentation for approximately 90
days.
About Revance
Revance is a biotechnology company setting the new standard in
healthcare with innovative aesthetic and therapeutic offerings that
enhance patient outcomes and physician experiences. Revance’s
portfolio includes DAXXIFY (daxibotulinumtoxinA-lanm) for injection
and the RHA® Collection of dermal fillers in the U.S. Revance has
also partnered with Viatris Inc. to develop a biosimilar to
onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical
to commercialize DAXXIFY in China.
Revance is headquartered in Nashville, Tenn., with additional
office locations in Newark and Irvine, Calif. Learn more at
Revance.com, RevanceAesthetics.com, DAXXIFY.com,
HCP.DaxxifyTherapy.com, or connect with us on LinkedIn.
“Revance”, the Revance logo, and DAXXIFY are registered
trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid®
and RHA® are trademarks of TEOXANE SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240221269040/en/
Investors Revance Therapeutics, Inc.: Jessica Serra,
510-279-6886 jessica.serra@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com Media
Revance Therapeutics, Inc.: Cathryn Castaldo, 615-245-7567
cathryn.castaldo@revance.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024